Press Releases Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
193.3 ^USD	-0.54%		-8.82%	-16.44%

Apr. 22	BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	MT
Apr. 22	BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period \| Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals	Apr. 26	AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison	Apr. 24	AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024	Apr. 24	AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024	Apr. 23	AQ
6 Stocks Positioned to Soar as Investors Focus on MASH	Apr. 22	AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Apr. 16	AQ
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 10	AQ
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 09	AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	AQ
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering	Mar. 18	AQ
Madrigal Pharmaceuticals Announces Proposed Public Offering	Mar. 18	AQ
Adobe, Ulta Beauty fall; Madrigal, Intuitive Surgical rise, Friday, 3/15/2024	Mar. 15	AQ
Madrigal Pharmaceuticals : Rezdiffra Approval Presentation	Mar. 14	PU
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis	Mar. 14	AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Mar. 06	AQ
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis	Mar. 05	AQ
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer	Feb. 28	AQ
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	AQ
Madrigal: Q4 Earnings Snapshot	Feb. 28	AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Feb. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Press Releases

Filters